55 related articles for article (PubMed ID: 38642578)
1. [The relationship between differentially expressed thyroid cancer genes and clinical characteristics in metastatic children and adolescents].
Pan YJ; Ju GD; Mu ZZ; Sun YQ; Sun D; Liang J; Lin YS
Zhonghua Yi Xue Za Zhi; 2024 May; 104(20):1837-1843. PubMed ID: 38782752
[No Abstract] [Full Text] [Related]
2. Projecting long-term clinical outcomes with larotrectinib compared with immune checkpoint inhibitors in metastatic nonsmall cell lung cancer and differentiated thyroid cancer.
Suh K; Kang A; Ko G; Williamson T; Liao N; Sullivan SD
J Manag Care Spec Pharm; 2024 Jun; 30(6):581-587. PubMed ID: 38824630
[TBL] [Abstract][Full Text] [Related]
3. Beyond Clinical Trials: Understanding Neurotrophic Tropomyosin Receptor Kinase Inhibitor Challenges and Efficacy in Real-World Pediatric Oncology.
Vince CSC; Brassesco MS; Mançano BM; Gregianin LJ; Carbone EK; do Amaral E Castro A; Dwan VSY; Menezes da Silva RZ; Mariano CS; da Mata JF; Silva MO; Caran EMM; Macedo CD; Alves da Costa G; Esteves TC; Silva LN; Ferman SE; Martins FD; Cristófani LM; Odone-Filho V; Silva MM; Reis RM; Pianovski MAD; Campregher PV; Kunii MS; de Sá Rodrigues KE; Carvalho Filho NP; Valera ET;
JCO Precis Oncol; 2024 May; 8():e2300713. PubMed ID: 38810175
[TBL] [Abstract][Full Text] [Related]
4. Sporadic pediatric papillary thyroid carcinoma harboring the ETV6/NTRK3 fusion oncogene in a 7-year-old Japanese girl: a case report and review of literature.
Otsubo R; Mussazhanova Z; Akazawa Y; Sato A; Matsuda K; Matsumoto M; Yano H; Matsuse M; Mitsutake N; Ando T; Niino D; Nagayasu T; Nakashima M
J Pediatr Endocrinol Metab; 2018 Mar; 31(4):461-467. PubMed ID: 29427554
[TBL] [Abstract][Full Text] [Related]
5. Radioiodine therapy in advanced differentiated thyroid cancer: Resistance and overcoming strategy.
Liu Y; Wang J; Hu X; Pan Z; Xu T; Xu J; Jiang L; Huang P; Zhang Y; Ge M
Drug Resist Updat; 2023 May; 68():100939. PubMed ID: 36806005
[TBL] [Abstract][Full Text] [Related]
6. Predictors of radioiodine (RAI)-avidity restoration for NTRK fusion-positive RAI-resistant metastatic thyroid cancers.
Syed AR; Gorana A; Nohr E; Yuan XK; Amin MASc P; Ghaznavi S; Lamb D; McIntyre J; Eszlinger M; Paschke R
Eur Thyroid J; 2024 Jun; 13(3):. PubMed ID: 38642578
[TBL] [Abstract][Full Text] [Related]
7.
Pekova B; Sykorova V; Mastnikova K; Vaclavikova E; Moravcova J; Vlcek P; Lastuvka P; Taudy M; Katra R; Bavor P; Kodetova D; Chovanec M; Drozenova J; Astl J; Hrabal P; Vcelak J; Bendlova B
Cancers (Basel); 2021 Apr; 13(8):. PubMed ID: 33923728
[TBL] [Abstract][Full Text] [Related]
8. Characterizing Genetic Alterations Related to Radioiodine Avidity in Metastatic Thyroid Cancer.
Mu Z; Zhang X; Sun D; Sun Y; Shi C; Ju G; Kai Z; Huang L; Chen L; Liang J; Lin Y
J Clin Endocrinol Metab; 2024 Apr; 109(5):1231-1240. PubMed ID: 38060243
[TBL] [Abstract][Full Text] [Related]
9. The Genetic Duet of
Liu J; Liu R; Shen X; Zhu G; Li B; Xing M
J Nucl Med; 2020 Feb; 61(2):177-182. PubMed ID: 31375570
[No Abstract] [Full Text] [Related]
10. Systematic population-based identification of NTRK and RET fusion-positive thyroid cancers.
Eszlinger M; Stewardson P; McIntyre JB; Box A; Khalil M; Hyrcza M; Koro K; Ruether D; Wu J; Paschke R
Eur Thyroid J; 2022 Jan; 11(1):. PubMed ID: 34981751
[TBL] [Abstract][Full Text] [Related]
11. NTRK fusion events and targeted treatment of advanced radioiodine refractory thyroid cancer.
Koehler VF; Achterfeld J; Sandner N; Koch C; Wiegmann JP; Ivanyi P; Käsmann L; Pusch R; Wolf D; Chirica M; Knösel T; Demes MC; Kumbrink J; Vogl TJ; Meyer G; Spitzweg C; Bojunga J; Kroiss M
J Cancer Res Clin Oncol; 2023 Nov; 149(15):14035-14043. PubMed ID: 37548775
[TBL] [Abstract][Full Text] [Related]
12. Prospective Validation of ThyroSPEC Molecular Testing of Indeterminate Thyroid Nodule Cytology Following Diagnostic Pathway Optimization.
Stewardson P; Eszlinger M; Wu J; Khalil M; Box A; Perizzolo M; Punjwani Z; Ziehr B; Sanyal R; Demetrick DJ; Paschke R
Thyroid; 2023 Dec; 33(12):1423-1433. PubMed ID: 37742115
[No Abstract] [Full Text] [Related]
13. MERAIODE: A Phase II Redifferentiation Trial with Trametinib and
Leboulleux S; Benisvy D; Taieb D; Attard M; Bournaud C; Terroir-Cassou-Mounat M; Lacroix L; Anizan N; Schiazza A; Garcia ME; Ghuzlan AA; Lamartina L; Schlumberger M; Godbert Y; Borget I
Thyroid; 2023 Sep; 33(9):1124-1129. PubMed ID: 37350119
[No Abstract] [Full Text] [Related]
14. A Phase II Redifferentiation Trial with Dabrafenib-Trametinib and 131I in Metastatic Radioactive Iodine Refractory BRAF p.V600E-Mutated Differentiated Thyroid Cancer.
Leboulleux S; Do Cao C; Zerdoud S; Attard M; Bournaud C; Lacroix L; Benisvy D; Taïeb D; Bardet S; Terroir-Cassou-Mounat M; Anizan N; Bouvier-Morel E; Lamartina L; Lion G; Betrian S; Sajous C; Schiazza A; Garcia ME; Ciappuccini R; Schlumberger M; Al Ghuzlan A; Godbert Y; Borget I
Clin Cancer Res; 2023 Jul; 29(13):2401-2409. PubMed ID: 37074727
[TBL] [Abstract][Full Text] [Related]
15. Redifferentiating Effect of Larotrectinib in
Groussin L; Theodon H; Bessiene L; Bricaire L; Bonnet-Serrano F; Cochand-Priollet B; Leroy K; Garinet S; Pasmant E; Zerbit J; Seban R; Goldwasser F; Clerc J; Cottereau AS; Huillard O
Thyroid; 2022 May; 32(5):594-598. PubMed ID: 35171708
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
